Leflunomide and Rosuvastatin Interaction

Understanding the Leflunomide and Rosuvastatin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Leflunomide belongs to the Disease-Modifying Antirheumatic Drug (DMARD) class and Rosuvastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Leflunomide changes how your body processes rosuvastatin, which can cause the amount of the cholesterol medicine in your blood to increase. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Leflunomide has 20 total documented interactions on file in this dataset, and Rosuvastatin has 21. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: If you are taking leflunomide, your daily dose of rosuvastatin should not be more than 10 mg. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Leflunomide or Rosuvastatin based on a web page, speak with your prescriber or pharmacist before making any change.